Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Feb 27, 2019
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two different treatments for early gastric cancer: a procedure called endoscopic submucosal dissection (ESD) and traditional surgery. Patients diagnosed with early gastric cancer will be enrolled and divided into two groups based on whether they receive ESD or surgery. They will be monitored for at least five years to see how well each treatment works and to check for any complications. Throughout the study, patients will have several follow-up tests, including endoscopies (a procedure to look inside the stomach) and CT scans, to track their progress and health.
To be eligible for this trial, patients must be diagnosed with early gastric cancer and be willing to undergo either ESD or surgery. However, those with advanced gastric cancer or who do not want to participate in the study will not be included. This trial aims to gather valuable information on the effectiveness and safety of these two treatment options, helping doctors understand which might be better for patients in the long run.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinically diagnosed as early gastric cancer
- • Willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer
- Exclusion Criteria:
- • Advanced stage gastric cancer
- • Not willing to undergo endoscopic submucosal dissection or surgery for the treatment of early gastric cancer
- • Not willing to participate in this study
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials